Cargando…
Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy
Hemophagocytic lymphohistiocytosis (HLH) is a fatal systemic inflammatory syndrome. HLH has been reported as a rare immune-related adverse event (irAE) in patients receiving immunotherapy with nivolumab, ipilimumab, and/or pembrolizumab. The data are limited to case reports and case series. The obje...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elmer Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076146/ https://www.ncbi.nlm.nih.gov/pubmed/35571340 http://dx.doi.org/10.14740/wjon1464 |